TY - JOUR T1 - Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 171 LP - 176 DO - 10.2967/jnumed.114.147256 VL - 56 IS - 2 AU - Nicolas Marincek AU - Piotr Radojewski AU - Rebecca A. Dumont AU - Philippe Brunner AU - Jan Müller-Brand AU - Helmut R. Maecke AU - Matthias Briel AU - Martin A. Walter Y1 - 2015/02/01 UR - http://jnm.snmjournals.org/content/56/2/171.abstract N2 - Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients. Methods: Patients with progressive unresectable meningioma were treated with 90Y-DOTATOC and 177Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival. Results: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001–0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004–0.63; n = 34; P = 0.019) were associated with longer survival. Conclusion: 90Y-DOTATOC and 177Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor. ER -